Trial Profile
A Phase II Study to Evaluate the Efficacy of Regorafenib in C-kit Mutated Metastatic Malignant Melanoma Failed First-Line Dacarbazine, Temozolomide or Immune Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Sep 2023
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 28 Aug 2023 Status has been to completed, as per Results published in the European Journal of Cancer
- 28 Aug 2023 Results published in the European Journal of Cancer
- 01 Apr 2021 Planned End Date changed from 1 Jun 2021 to 1 Jun 2022.